A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Japanese Subjects With Hematological Malignancies

Trial Profile

A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Japanese Subjects With Hematological Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs Venetoclax (Primary) ; Azacitidine; Azacitidine; Rituximab
  • Indications Chronic lymphocytic leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 18 Sep 2017 Trial phase has been changed from phase I to phase I/II. Also two new drugs (Azacitidine and Rituximab) has been added in the study.
    • 18 Sep 2017 Planned primary completion date changed from 17 Apr 2017 to 6 Feb 2020.
    • 25 Jun 2017 Results (n=20) presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top